Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of a New Drug Treatment for Acne

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01326780
Recruitment Status : Completed
First Posted : March 31, 2011
Results First Posted : December 11, 2018
Last Update Posted : October 16, 2019
Sponsor:
Information provided by (Responsible Party):
Bausch Health Americas, Inc.

Brief Summary:
A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: 1.2% JNJ 10229570-AAA Drug: 2.4% JNJ 10229570-AAA Drug: 3.6% JNJ 10229570-AAA Other: Vehicle control Phase 2

Detailed Description:
Approximately 400 male and female subjects with moderate facial acne vulgaris will be enrolled in this randomized, multi-center study. Following satisfaction of entry criteria and screening procedures, subjects will be randomized to either 1.2%, 2.4%, or 3.6% facial cream (JNJ 10229570-AAA) or color-matched vehicle. Subjects will apply the study medication once daily on the face for 12 weeks. Safety will be monitored throughout the study duration. Efficacy will be assessed by facial lesion counts and by the investigator global evaluation of acne severity at Baseline and at Weeks 2, 4, 6, 8, 10, and 12. Approximately 50 subjects from one investigational site also will have serums collected at Weeks 6 and 12 for evaluation of the multiple dose pharmacokinetics of JNJ 10229570-AAA cream.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 431 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Double-Blind, Vehicle Controlled, Phase II Study of JNJ 10229570-AAA for the Treatment of Acne Vulgaris
Actual Study Start Date : March 31, 2011
Actual Primary Completion Date : March 31, 2012
Actual Study Completion Date : March 31, 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Experimental: 1.2% Facial Cream
1.2% JNJ 10229570-AAA
Drug: 1.2% JNJ 10229570-AAA
1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
Other Name: Not yet marketed

Experimental: 2.4% Facial Cream
2.4% JNJ 10229570-AAA
Drug: 2.4% JNJ 10229570-AAA
2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
Other Name: Not yet marketed

Experimental: 3.6% Facial Cream
3.6% JNJ 10229570-AAA
Drug: 3.6% JNJ 10229570-AAA
3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
Other Name: Not yet marketed

Placebo Comparator: 0% Facial Cream
Vehicle control
Other: Vehicle control
Color matched cream vehicle, applied once daily to the face for 12 weeks
Other Name: Not marketed




Primary Outcome Measures :
  1. Change in Total Acne Lesion Counts [ Time Frame: Baseline to Week 12 ]
    Change in lesion counts between baseline and end of study


Secondary Outcome Measures :
  1. Change From Baseline in the Non-inflammatory Acne Lesion Counts [ Time Frame: Baseline through Week 12 ]
    Change in sum of open and closed comedones.

  2. Change From Baseline in the Inflammatory Acne Lesion Counts [ Time Frame: Baseline through Week 12 ]
    Change in sum of papules and pustules

  3. Percent Change From Baseline in the Non-Inflammatory Acne Lesion Counts [ Time Frame: Baseline through Week 12 ]
    Percent Change in the Non-Inflammatory Acne Lesion Counts (the sum of open and closed comedones)

  4. Percent Change From Baseline in the Inflammatory Acne Lesion Counts [ Time Frame: Baseline through Week 12 ]
    Percent Change in Inflammatory Acne Lesion Counts (sum of of papules and pustules)

  5. Percent Change From Baseline in Total Acne Lesion Counts [ Time Frame: Baseline through Week 12. ]
    Percent change in Total Acne Lesion Counts (inflammatory lesions and non-inflammatory lesions)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 12 years of age or older, with moderate facial acne vulgaris as defined in the protocol
  • If female of childbearing potential, must take a pregnancy test and have a negative result
  • Females of childbearing potential must also agree to use an adequate method of birth control, which would include:

    • systemic birth control (Subjects must have been taking the same type of birth control for at least 3 months prior to entering the study and must not change type of birth control during the study)
    • Condom with spermicide
    • IUD. Females who have had a hysterectomy, bilateral oophorectomy or bilateral tubal ligation are not required to use additional birth control methods

Exclusion Criteria:

  • Known sensitivity to any of the ingredients in the study medication
  • More than 3 nodulocystic acne lesions
  • Use of acne treatments, therapies or medications within protocol-specified timeframes
  • Presence of other skin conditions, diseases, or medical conditions that (per protocol or in the opinion of the investigator) may require concurrent therapy, interfere with the evaluation of the study medication, or compromise subject safety
  • Excessive facial hair that may interfere with application of the medication and/or evaluations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01326780


Locations
Layout table for location information
United States, California
University of California, San Diego
San Diego, California, United States, 92093
University Clinical Trials, Inc.
San Diego, California, United States, 92123
United States, Colorado
Thomas J. Stephens & Associates, Inc.
Colorado Springs, Colorado, United States, 80915
Horizons Clinical Research Ctr., LLC
Denver, Colorado, United States, 80220
United States, Florida
North Florida Dermatology
Jacksonville, Florida, United States, 32204
Hilltop Research
Saint Petersburg, Florida, United States, 33710
United States, Georgia
Gwinnett Clinical Research
Snellville, Georgia, United States, 30078
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Kentucky
Dermatology Specialists Research, Inc
Louisville, Kentucky, United States, 40202
United States, Minnesota
Minnesota Clinical Study Center
Fridley, Minnesota, United States, 55432
United States, New Jersey
TKL Research
Rochelle Park, New Jersey, United States, 07662
United States, New Mexico
Academic Dermatology Associates
Albuquerque, New Mexico, United States, 87106
United States, North Carolina
Wake Research Associates
Raleigh, North Carolina, United States, 27612
United States, Ohio
Hilltop Research
Miamiville, Ohio, United States, 45147
United States, Pennsylvania
Penn State Medical Center
Hershey, Pennsylvania, United States, 17033
Yardley Dermatology Associates
Yardley, Pennsylvania, United States, 19067
United States, Texas
Research Across America
Dallas, Texas, United States, 75234
Reliance Clinical Testing Services
Irving, Texas, United States, 75062
Sponsors and Collaborators
Bausch Health Americas, Inc.
Investigators
Layout table for investigator information
Study Director: Johnson Varughese Bausch Health Americas, Inc.

Additional Information:
Layout table for additonal information
Responsible Party: Bausch Health Americas, Inc.
ClinicalTrials.gov Identifier: NCT01326780     History of Changes
Other Study ID Numbers: CA-P-8023
First Posted: March 31, 2011    Key Record Dates
Results First Posted: December 11, 2018
Last Update Posted: October 16, 2019
Last Verified: October 2019
Keywords provided by Bausch Health Americas, Inc.:
Acne
Irritation
Safety
Sebum
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases